Specimen for raise of productivity and resistance of animals

FIELD: agriculture.

SUBSTANCE: specimen consists of polyzones and thiamine bromide at a following relation of components (in mass fraction): polyzones - 80...60, thiamine bromide - 20...40.

EFFECT: specimen has a hyperactivity growth-stimulating effect and raises resistance of animals to sicknesses of a gastrointestinal tract.

5 tbl

 

The invention relates to veterinary medicine, in particular to the growth-promoting means animals, and can be used to activate and treatment of diseases of the gastrointestinal tract, and ulcerative diseases.

The prototype of the invention is Polison formula

The disadvantage of the prototype is weak growth-stimulating effect and the absence of activation and treatment of the gastrointestinal tract.

The invention allows to obtain a new effect : increases the growth-promoting effect, has the properties of activation and treatment of diseases of the gastrointestinal tract, and ulcerative diseases.

This technical effect is achieved by the fact that impose additional Thiamine bromide ratio, parts:

Polison80...60
Thiamine bromide20...40

The composition of Polison contains 80...60% of Polison (phosphate salt of 2-amino-4-methylthio-(S-oxo-S-imino)-butyric acid) and 20...40% of vitamin B1(4-methyl-5-β-oxyethyl-N-(2-methyl-4-amino-5-methylpyrimidin)-tiazoly bromide).

pH of 1%solution of 4.

The product is a white powder or white with a slightly yellowish ottensamer weak characteristic smell of yeast.

Comes in a 2%, 5% powder.

Sredneseriynoe dose Polison is for white mice - 1070,0±89,40 mg/kg for white rats - 1454,17±79,32 mg/kg Sredneseriynoe dose composition Polison + Thiamine bromide for white mice were: 1615,0±101,1 mg/kg, for rats - 2050,6±180,6 mg/kg

The preparation should be stored in the packaging manufacturer in a dry, dark place at temperatures from minus 20°C to 40°C. the shelf Life is 3 years from date of manufacture.

The INFLUENCE of COMPOSITION POLISON + THIAMINE BROMIDE ON the SECRETORY ACTIVITY of the GASTROINTESTINAL TRACT

In the pathogenesis of disorders of the gastrointestinal tract is a sum of factors, between which there is a causal relationship: the increase in total acidity and hydrochloric acid gastric contents, reducing the number of bound and free hydrochloric acid; fermentopathy, manifested by reduced digestive ability; intoxication; metabolic disorders; degeneration of organs and tissues.

The material was 60 patients with gastroenteritis of pigs selected according to the principle analogues, at the age of 3 months, which were divided into 6 groups of 10 animals each:

Group I - got Polison at a dose of 5 mg/kg;

Group II - composition Polison + Thiamine bromide in a ratio of 80-60:20-40 parts;

Group III - it is nosily Polison + Thiamine bromide in a ratio of 90-80:10-20 parts;

Group IV - composition Polison + Thiamine bromide in a ratio of 60-40:40-60 parts;

Group V - Thiamine bromide at a dose of 4 mg/kg;

Group VI - control animals.

The piglets of the experimental groups were administered the compounds for 10 days. Piglets of group IV were treated with the conventional method.

The research results are reflected in table 1.

Table 1

Influence on the secretory activity of the gastrointestinal tract of pigs
no groupThe total acidity of the gastric contents (titer. unit)Free hydrochloric acid of the gastric contents (titer. unit)Related hydrochloric acid of the gastric contents (titer. unit)Digestive power of the stomach contents (mm)
The source data
77,4±7,378,5±0,127,8±0,180,7±0,02
5 day
I61,8±4,8410,7±0,4810,1±1,010,9±0,13
II58,5±3,8115,9±1,4913,1±1,051,2±0,09
III62,3±2,989,9±0,91 9,3±0,850,8±0,04
IV63,7±5,2710,1±1,019,2±0,880,9±0,05
V66,8±5,958,7±0,82a 9.5±0,170,8±0,06
VI73,4±6,938,0±0,618,5±0,790,7±0,05
day 10
I58,7±4,3315,5±1,0115,8±1,082,0±0,29
II47,4±2,8823,2±2,0115,5±0,935,2±0,46
III55,3±3,5916,6±1,0511,4±1,061,9±0,15
IV57,6±5,2713,8±1,2212,1±0,951,6±0,12
V60,8±4,6210,0±2,1310,1±1,641,5±0,18
VI69,7±5,669,4±3,29a 9.5±1,851,1±0,11
Note: P<0,001

We established that during the height of the disease in piglets observed a significant increase in total acidity (77.4 title. units), while the soda is the content of free and bound hydrochloric acid is reduced (8,5± 0.12 and 7,8±0.18 titer. units), also reduced digestive ability, which is associated with insufficient content of pepsin in the gastric contents. On day 5 of treatment in animals of the first group there is a decrease in total acidity (to 61.8±4,84 the title. units), the amount of free and bound hydrochloric acid increased to 10.7±0,48 and 10.1±1.01 title. units respectively. Digestive ability remained at a sufficient low level (0,9±0.13 mm). In animals of group II total acidity (58,5±3,81 the title. units) and the content of free and bound hydrochloric acid (15,9±1,99 and 12.1±1,65 titer. damage) are normal. Digestive power of the stomach contents also increased significantly (1,2±0.09 mm). In piglets of groups III and IV indicators of functional status have only a slight positive trend. After 10 days, we found that in animals of groups I and II indicators are normal, whereas in piglets of groups III and IV functional status of the digestive system is in poor condition.

Therefore, the data obtained indicate that the composition Polison + Thiamine bromide helps to restore the function of the gastrointestinal tract due to the normalization of the content of total acidity, free and bound hydrochloric acid, and enhanced excretion of enzymes.

PROTIVOYAZVENNO THE ACTIVITY COMPOSITION POLISON + THIAMINE BROMIDE

Presented in tables 2 and 3 one can see that the antiulcer activity of Thiamine bromide, put the animal in a dose of 4 mg/kg was 2,62; Polison, in the dose of 5 mg/kg 4,0; composition Polison + Thiamine bromide in a ratio of 60-40:40-60 parts was 4.42; composition Polison + Thiamine bromide in a ratio of 90-80:10-20 parts - 4,66, and antiulcer activity of the composition Polison + Thiamine bromide in a ratio of 80-60:20-40 parts - 5,12 when used as ulcerogenic substances solution of acetylsalicylic acid. When applying indometacin obtained the following results: with the introduction of Thiamine bromide, put the animal in a dose of 4 mg/kg, antiulcer activity was 1.14; Polison at a dose of 5 mg/kg 1,60; composition Polison + Thiamine bromide in a ratio of 60-40:40-60 parts - 1.64 and in the ratio 90-80:10-20 parts - 2,48, using the composition Polison + Thiamine bromide in a ratio of 80-60:20-40 parts - 2,78. The drug is considered effective if its antiulcer activity of > 2.

Table 2

The influence of Polison and composition Polison + Thiamine bromide on the development of experimental "aspirin-induced ulcers in rats
Aspirin
The connection nameDoseThe average number of ulcersIndex PA the forest Antiulcer activityThe level of reliabilityP
Thiamine bromide4 mg/kg8,0±1,7882,625,663P<0,01
Polison5 mg/kgthe 5.25±0,53the 5.254,02,718P<0,05
Polison + Thiamine bromide60-40:40-60 parts4,75±1,104,754,423,528P<0,02
90-80:10-20 parts4,5±0,644,5of 4.662,054P>0,1
80-60:20-40 parts4,1±0,324,15,122,601P<0,05
Control-21,0±1,7821-5,663P<0,01

Table 3

The influence of Polison and composition Polison + Thiamine bromide on the development of experimental indomethacin ulcers in rats
Indometacin
The connection nameDoseThe average number of ulcersIndex Paulesu Antiulcer activityThe level of reliabilityP
Tianna bromide4 mg/kg25,5±3,5925,51,1411,438P<0,001
Polison5 mg/kg18,25±1,6518,251,605,257P<0,01
Polison + Thiamine bromide60-40:40-60 parts17,75±2,6217,751,648,357P<0,001
90-80:10-20 parts11,75±0,6211,752,482,002P>0,1
80-60:20-40 parts10,54±0,9410,542,785,553P<0,01
Control29,25±1,3729,25-4,382P<0,01

The results showed that when using as ulcerogens acetylsalicylic acid best antiulcerogenic effect we observed in the application of the composition Polison + Thiamine bromide in a ratio of 80-60:20-40 parts; when using indometacin studied composition had a strong antiulcer effect in relation 80-60:20-40 parts

p> The INFLUENCE of COMPOSITION POLISON + THIAMINE BROMIDE ON the WEIGHT of INTERNAL ORGANS of RATS

Experiments to study the influence of composition Polison + Thiamine bromide at a dose of 2+2 mg/kg on the weight of the organs of the gastrointestinal tract (stomach, liver, pancreas) and total body weight of the animals was carried out on outbred white rats with body weight 120-130, Used 16 animals, divided into 2 groups: experimental and control. The drug was administered in the dose of 2+2 mg/kg intragastric tube for 10 days. After 10 days, animals were scored and weighed.

Table 4 summarizes the statistically processed data on weight of internal organs of rats.

Table 4

The influence of composition Polison + Thiamine bromide on the weight of internal organs of rats after daily oral administration for 10 days
MedicationNumber of animals in the groupStatisticsStomach, gLiver, gPancreas, gThe mass of rats, g
Control8M±m0,585±0,1194,416±0,300,156±0,011124,5±the remaining 9.08
Polison + Thiamine bromide M±m0,893±0,2895,950±0,2850,255±0,015139,9±10,11
PP>0,5P>0,5P>0,5P>0,5

In the analysis of the table shows that rats under the influence of the studied composition there is an increase in total body mass of the animal (15.4 g compared to control animals) and the weight of internal organs: the mass of the stomach in the experimental group more than in the control 0,308 g; liver - 1,534 g; pancreas - 0,099,

Thus, the composition Polison + Thiamine bromide at a dose of 2+2 mg/kg, given for 10 days, has a stimulating effect on the development of the entire body and organs of the gastrointestinal tract: stomach, liver and pancreas.

The INFLUENCE of COMPOSITION POLISON + THIAMINE BROMIDE AND POLISON ON the weight GAIN of the PIGLETS

Table 5

The influence of composition Polison+Thiamine bromide and Polison on average daily weight gain of piglets
no groupName of productDoseQty alive x in the group goal.Weight of piglets up to experience, kgWeight of piglets after experience, kgThe absolute growth rate, kgtoitaly growth, %Average resistant gain, g
1Polison5 mg/kg1029,7±2,1744,2±4,1214,548,82690,0±3,01
2Polison + Thiamine bromide80-60:20-40 parts1029,1±1,9745,6±4,3316,556,70786,0±4,07
3Polison + Thiamine bromide60-40:40-60 parts1029,5±of 2.5140,3±3,9412,843,39609,0±2,04
4Control-1029,3±2,3230,7±3,7511,438,91543,0±3,11
Note: P<0,05

Analyzing the results of table 5, we note that the highest average daily relative and absolute increases were observed in piglets treated with the composition Polison + Thiamine bromide in a ratio of 80-60:20-40 parts

The ORDER of APPLICATION

Composition Polison + Thiamine bromide has a pronounced anti-ulcer effect.

Composition Polison + Thiamine bromide has an antibacterial effect and can be used in practice for the treatment of diseases, caused by Escherichia coli.

Composition Polison + Thiamine bromide contributes to a more significant increase of total protein and amino acids in the serum compared with Polison, which positively affects the fattening qualities of pigs. Also promotes the activation of protein metabolism, resulting in increased resistance of the body, accelerate the pace of growth.

Composition Polison + Thiamine bromide contributes to the activation of phagocytic activity of the reaction of neutrophils of blood against Escherichia coli and humoral factors of nonspecific protection in piglets.

Composition Polison + Thiamine bromide helps to restore the function of the gastrointestinal tract due to the normalization of the content of total acidity, free and bound hydrochloric acid, and enhanced excretion of enzymes.

Composition Polison + Thiamine bromide asked, thoroughly mixed with the feed, individually or by group method daily calculation of the pigs 5+4 mg/kg

Products of slaughter animals used for food purposes without restrictions.

When using the drug in the recommended quantities of side effects and complications are not installed. There are no contraindications.

PRECAUTIONS

When working with the product should comply with the normal rules of personal hygiene and techniques of the security.

Empty containers of the drug he is neutralized by boiling in 5%solution of soda.

Sources of information

1. Strunin BP Biologically active functionalityand amino acids: amino acids: synthesis, structure, technology, abstract of dissertation for the degree of doctor of technical Sciences. - Kazan. - 2005. - 37 S. (prototype).

Drug to increase productivity and resistance of animals, including polison, characterized in that it further contains thiamine bromide in the following ratio of ingredients, in parts by weight:

Polison80-60
thiamine bromide20-40



 

Same patents:

FIELD: medicine, angiocardiosurgery, gastroenterology.

SUBSTANCE: the present innovation deals with endoscopic treatment of gastroduodenal ulcers in angiocardiosurgical patients. One should endoscopically apply gel containing 3%-aqueous solution of sodium carboxymethyl cellulose and 5%-oxymethyl uracil upon the ulcer. Single dosage corresponds 5-10 ml, the course - about 3-4 seances every 1-2 d. The innovation provides polycomponent impact of the mentioned medicinal preparation and, thus, shortened terms of pre-surgical preparatory procedures in angiocardiosurgical patients upon the main disease, the prevention of the development of its complicated forms.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine.

SUBSTANCE: method involves detecting duodenum wall integrity disorders in performing endoscopic examination of duodenal ulcer after removing necrotic detritus from ulcer bottom. Available wall defect is subjected to endoscopic probing with catheter introducing water-soluble radiopaque solution through the probe and followed with fistulographic examination. The radiopaque solution being observed outside of duodenum, duodenal fistula or perforated ulcer are diagnosed.

EFFECT: high reliability of early stage diagnosis.

3 dwg

FIELD: medicine.

SUBSTANCE: method involves giving magnesium-sodium-hydrocarbonate mineral water of moderate mineralization degree at room temperature in the amount of 150-200 ml. 20-30 min later alternating electromagnetic field operating in low frequency bandwidth of 0.022 Hz-270 kHz is administered in scanning mode of 43 produced by Rematherp apparatus. The total treatment course is 8-10 procedures long.

EFFECT: enhanced effectiveness of treatment; stimulated reparative processes in esophageal mucous membrane.

FIELD: medicine.

SUBSTANCE: method involves introducing Omeprasol at a dose of 20 mg twice a day before taking meals 10 days long, Amoxycillin at a dose of 1000 mg twice a day after breakfast and supper 7 days long, Clarithromycin at a dose of 500 mg twice a day before taking meals and Imudon as local immunomodulating factor at a dose of 8 pills a day making 2-3 h long pauses for resolving drug in oral cavity within 10 days.

EFFECT: enhanced effectiveness of treatment; reduced reinfection risk.

2 tbl

FIELD: medicine, gastroenterology, pediatrics.

SUBSTANCE: method involves using drugs directed on eradication of microorganism Helicobacter pylori that comprises the preparation "Vetoron" additionally. The preparation "Vetoron" is prescribed in the dose 6-8 drops to children of age 7-12 years and in the dose 8-10 drops to children of age 13-17 years for 7-10 days. Invention provides decreasing the mutagenic effect in carrying out the anti-helicobacter therapy in children. Invention can be used in treatment of children suffering from diseases of upper regions of digestive tract associated with infection with Helicobacter pylori.

EFFECT: improved method of treatment.

3 tbl, 2 ex

FIELD: medicine, pharmaceutical.

SUBSTANCE: invention relates to solid composition for treatment of reflux esophagitis, gastritis, or ulcers, method for production thereof and uses in therapy. Claimed composition contains alginate, bicarbonate and/or carbonate, and poly(C1-C5-alkylene glycol) hawing molecular mass of at least 6000 in amount of 1-50 %.

EFFECT: composition of decreased foam-forming properties and improved organoleptic characteristics.

12 cl, 18 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to using compounds of (R,S)-2-arylpropionic acids of the formula (Ia) , and their (R)- and (S)-isomers as inhibitors of neutrophile (PMN leukocytes) chemotaxis induced by IL-8. These compounds elicit unexpected ability to inhibit effectively IL-8-induced chemotaxis and degranulation of neutrophiles being without significant effect on activity of cyclooxygenases. These compounds can be used in treatment of such diseases as psoriasis, ulcerated colitis, melanoma, chronic obstructive pulmonary disease, bulla pemphigus, rheumatic arthritis, idiopathic fibrosis, glomerulonephritis, and for prophylaxis and treatment of damages induced by ischemia and reperfusion.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

9 cl, 3 tbl, 43 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel derivatives of carboxylic acid represented by the general formula (I): , their pharmaceutically acceptable salts or esters wherein values Y, L, X, T, Z, M, R1, W and are given in the invention claim. Proposed compounds possess insulin-sensitizing effect and they are double agonists with respect to PPARα and γ, and triple agonists with respect to PPARα, β(δ) and γ. Except for, the invention relates to a medicinal agent and pharmaceutical compositions based on the claimed derivatives of carboxylic acid, to methods for prophylaxis or treatment of diseases, and to using derivatives carboxylic acid for preparing a medicinal agent.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

56 cl, 2 tbl, 609 ex

FIELD: medicine, gastroenterology, surgery.

SUBSTANCE: starting since the 2nd d after operation it is necessary to have a daily twice peroral intake of 200-300 ml ozonized distilled water at ozone concentration being 4-6 mg/l and intragastric injection of ozone-oxygen mixture (OOM). On the 5-6th d after operation in case of fibrogastroduodenoscopy (FGDS) it is important to inject per 4-5 ml ozonized physiological solution (OPS) at ozone concentration of 2-4 mg/l submucosally along the perimeter of the sutured ulcer, at about 4-5 mm against its edges, from 4 equidistant points. Then it is necessary to carry out ulcer's application with "Ozonide" oil. After that OOM should be injected at ozone concentration ranged 20-25 mg/l till the appearance of bulging out feeling in area of a patient's epigastrium. The above-mentioned procedures should be repeated every 3-4 d till complete ulcer's healing. The innovation shortens the terms of lysis of necrotic masses, improves reparative processes in the sutured wound and decreases inoculation degree with Helicobacter pylori in gastric and duodenal mucosa.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, gastroenterology, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition used in treatment of diseases of digestive tract accompanying with disturbance of acid formation in stomach and/or ulceration of stomach and/or duodenum mucosa. The composition comprises sucralfate in a single dose from 0.25 g to 1.0 g or aluminum phosphate in a single dose from 3.8 g to 16.0 g, and prebiotic - fructooligosaccharide in a single dose from 2.5 g to 16.0 g and this composition is taken 1-3 times per 24 h. Also, invention relates to a method for preparing and using this composition. Proposed pharmaceutical composition promotes to acceleration of ulcer defect epithelization being independently on areas of ulcer defect and acidity of the stomach content.

EFFECT: improved and valuable medicinal properties of pharmaceutical composition.

8 cl, 8 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: film dosage form sticking to mucous, containing at least on active substance from hemp. The form contains the polymeric matrix, which is used as a reservoir for the active substance and sticking to mucous. The form can have the multilayer structure. It can also contain the non-active ingredients, odorants or aromatisors. The film form is used in treatment of pain in such diseases as carcinomatosis, AIDS, trauma and other disorders.

EFFECT: invention provides better tolerance to administered substances and rapid onset of administered drug, simplifies administration procedures.

19 cl

FIELD: medicine.

SUBSTANCE: concentrated solution of stabilized ozone for treatment of inflammatory processes contains the ozone carrier, which includes the isotonic saline and ozone, and in addition, perfluorocarbon or mixture of perfluorocarbons and the surfactant. The components are taken in particular amount.

EFFECT: concentrated solution of stabilized ozone has long-lasting antimicrobial activity and storage time.

6 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: target goal is resolved by combined therapy, which consists of 2 stages: out-patient home-based treatment and in-patient treatment at sanatorium-and-spa. The second stage starts immediately after the first one is completed. At the first stage, the oxygen and the blood supplies of the central nervous system, cerebral cortex, optic tract, anterior eye segment. During the second stage at sanatorium-and-spa, the therapy proper of myopia and amblyopia is performed by use of medicamentous, physical and electrophysiological methods. Irifrin, Arutimol, Vasobral, Mydriacyl and Catachrome are used in medicamentous therapy.

EFFECT: visual acuity is improved and long-term preservation is achieved.

5 cl, 1 tbl, 4 ex

Compound // 2323940

FIELD: chemistry.

SUBSTANCE: photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

EFFECT: compounds are widely used as photosensitising agents for photochemical internalisation of molecules and photodynamic therapy.

25 cl, 8 ex, 8 dwg

Indanol derivatives // 2323937

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I): (where R1 and R2 may be identical or different, and each is a 1,3-substituted aryl with substituents from group α; R3 stands for any of the following groups: -CO-R4, -CO-O-R4, -CO-NH-R4, -CO-CH2-N(Ra)Rb, -(CH2)m-CO-R5, -(CH2)m-R5, -CO-NH-CO-N(Ra)Rb, -CO-NH-SO2-N(Ra)Rb, -CO-NH-CO-(CH2)m-N(Ra)Rb, or -CO-NH2; R4 stands for a lower alkyl, cycloalkyl, cycloalkyl substituted with 1-3 substituent from group α, lower alkenyl, lower alkynyl, halogen-substituted lower alkyl, hydroxyl-substituted lower alkyl, lower alkoxyalkyl, lower aliphatic acyloxyalkyl or lower alkoxycarbonylalkyl; R5 stands for hydroxyl, -OR4 or -N(Ra)Rb; Rа and Rb may be identical or different, each of them stands for hydrogen, hydroxyl, lower alkoxy group, hydroxyl-substituted lower alkoxyl, hydroxyl-substituted lower alkoxyalkyl, lower alkoxy lower alkoxyalkyl, cyano lower alkyl, cyano lower alkoxyalkyl, carboxy lower alkyl, carboxy lower alkoxyalkyl, aliphatic lower alkoxycarbonyl lower alkoxyalkyl, carbamoyl lower alkyl group, carbamoyl lower alkoxyalkyl, lower aliphatic acylamino lower alkyl, lower aliphatic acylamino lower alkoxyalkyl, lower alkylsulphonylamino lower alkyl, lower alkylsulphanylamino lower alkoxyalkyl, (N-hydroxy-N-methylcarbamoyl) lower alkyl, (N-hydroxy-N-methylcarbamoyl) lower alkoxyalkyl, (N-lower alkoxy-N-methylcarbamoyl) lower alkyl, (N-lower alkoxy-14-methylcarbamoyl) lower alkoxyalkyl or R4, or both, including associated nitrogen, stand for nitrogen-containing heterocyclic group or nitrogen-containing 1-3 substituted heterocyclic group with substituents from group α; m is an integer from 1 to 6; А stands for carbonyl; В stands for straight bond; D stands for oxygen atom; Е stands for С14 alkylene; n is an integer from 1 to 3; and α group is a group of substituents, which consist of halogen atoms, lower alkyls, hydroxy lower alkyls, halogen lower alkyls, carboxy lower alkyls, lower alkoxyls, hydroxy lower alkoxyls, hydroxy lower alkoxyalkyls, lower alkoxycarbonyls, carboxyls, hydroxyls, lower aliphatic acyls, lower aliphatic acylamines, (N-hydroxy-N-methylcarbamoyl) lower alkyls, (N-lower alkoxy-N-methylcarbamoyl) lower alkyls, hydroxy lower aliphatic acylamines, amines, carbamoyls and cyano groups), or pharmacologically suitable salt thereof. Invention also relates to pharmaceutical composition and method for disease prevention and treatment.

EFFECT: preparation of novel biologically active compounds.

18 cl, 117 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically suitable salt or solvate thereof, where dashed line stands for additional bond, а is a number from 0 to 2, b is a number from 0 to 2, n is 2, p is 2, r is 1, М1 stands for nitrogen, М2 stands for С(R3), X stands for either a bond or alkylene group with number of carbon atoms from 1 to 6, Y stands for -С(О)- group, Z stands for a bond, or alkylene group with number of carbon atoms from 1 to 6, or alkenylene group with number of carbon atoms from 1 to 6, or -С(O)-, -CH(CN)-, -SO2- or СН2С(O)NR4- group, R1 stands for groups, R2 stands for six-membered heteroaryl ring with one or two heteroatoms chosen independently of each other from either nitrogen atom or N-O group, other atoms of the cycle being carbon, five-membered heteroaryl ring with one, two, three or four heteroatoms chosen independently of each other from nitrogen, oxygen or sulphur, other atoms of the cycle being carbon, R32 stands for substituded quinoline group, R32 stands for substituted aryl group, heterocycloalkyl group, cycloalkyl group with number of carbon atoms from 3 to 6, alkyl group with number of carbon atoms from 1 to 6, group, where the said six-membered heteroaryl ring or the said five-membered heteroaryl ring may be R6-substituted, R12 independently of others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group or fluorine atom, provided in case R12 stands for hydroxyl or fluorine the rest of R12 cannot be bonded to a nitrogen-bonded carbon atom, or two R12 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjaicent carbon atoms of the ring, R13 independently of the others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group, alcoxy group with number of carbon atoms from 1 to 6, or fluorine atom, provided in case R13 stands for hydroxyl or fluorine the rest of R13 cannot be bonded to a nitrogen-bonded carbon atom, or two R13 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjacent carbon atoms of the ring. See description for meaning of the other structural elements. Invention relates also to pharmaceutical compositions, as well as to application of compounds of formula I.

EFFECT: preparation of novel biologically active substances and pharmaceutical compositions.

20 cl, 659 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically suitable salt or solvate thereof, where dashed line stands for additional bond, а is a number from 0 to 2, b is a number from 0 to 2, n is 2, p is 2, r is 1, М1 stands for nitrogen, М2 stands for С(R3), X stands for either a bond or alkylene group with number of carbon atoms from 1 to 6, Y stands for -С(О)- group, Z stands for a bond, or alkylene group with number of carbon atoms from 1 to 6, or alkenylene group with number of carbon atoms from 1 to 6, or -С(O)-, -CH(CN)-, -SO2- or СН2С(O)NR4- group, R1 stands for groups, R2 stands for six-membered heteroaryl ring with one or two heteroatoms chosen independently of each other from either nitrogen atom or N-O group, other atoms of the cycle being carbon, five-membered heteroaryl ring with one, two, three or four heteroatoms chosen independently of each other from nitrogen, oxygen or sulphur, other atoms of the cycle being carbon, R32 stands for substituded quinoline group, R32 stands for substituted aryl group, heterocycloalkyl group, cycloalkyl group with number of carbon atoms from 3 to 6, alkyl group with number of carbon atoms from 1 to 6, group, where the said six-membered heteroaryl ring or the said five-membered heteroaryl ring may be R6-substituted, R12 independently of others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group or fluorine atom, provided in case R12 stands for hydroxyl or fluorine the rest of R12 cannot be bonded to a nitrogen-bonded carbon atom, or two R12 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjaicent carbon atoms of the ring, R13 independently of the others is chosen from an alkyl group with number of carbon atoms from 1 to 6, hydroxyl group, alcoxy group with number of carbon atoms from 1 to 6, or fluorine atom, provided in case R13 stands for hydroxyl or fluorine the rest of R13 cannot be bonded to a nitrogen-bonded carbon atom, or two R13 substituents form an alkyl bridge with number of carbon atoms from 1 to 2, which bonds two non-adjacent carbon atoms of the ring. See description for meaning of the other structural elements. Invention relates also to pharmaceutical compositions, as well as to application of compounds of formula I.

EFFECT: preparation of novel biologically active substances and pharmaceutical compositions.

20 cl, 659 ex

FIELD: medicine, pharmacology.

SUBSTANCE: compound formula I is described, including the pharmaceutically acceptable salts, , where: Z presents ; Q is taken from the group that consists of: -W - presents , and the pharmaceutical composition, application of compound formula (I) for preparation of antiviral medicine.

EFFECT: proposed compounds can be helpful in treatment of HIV and AIDS.

70 cl, 2 tbl, 129 ex

FIELD: chemistry.

SUBSTANCE: invention relates to crystallic hydrate of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one of example В1, to method for preparation thereof, to anhydrous crystalline forms of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one of examples D1, С1, Е1, as well as to pharmaceutical composition. Technical effect - easy commercial preparation of 3-(2-cyanophenyl)-5-(2-pyridyl-1-phenyl-1,2-dihydropyridine-2-one as a homogeneous crystalline form, which is an АМРА receptor antagonist and/or kainate receptor inhibitor.

EFFECT: facilitation of dyhydropyridine preparation.

26 cl, 9 ex, 11 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: description is provided for the derivative of phenylalcan or phenyloxyalcan acids, formula (I), or their pharmaceutically acceptable salt or hydrolysable ester, where: R1 and R2 independently present the H or С1-3alkyl; X presents the O or (СН2)n where n is 0.1 or 2; R3 and R4 independently present the H, С1-3alkyl, -ОСН3, CF3, allyl or halogen; X1 presents О, S, SO2, SO or СН2; one of R5 and R6 independently presents hydrogen, and another - С1-6alkyl (including the ramified alkyl and, probably, the substituted С1-6alkoxy); R7 presents a phenyl or hexamerous heterocycle taken from pyridine, and each of specified phenyl or heterocycles is substituted by phenyl (probably, substituted by one ore more С1-3alkyl, CN, halogen or CF3). The pharmaceutical composition is also described.

EFFECT: compounds can be used in treatment of cardiovascular and endocrine diseases.

13 cl, 145 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

Up!